Exp Clin Endocrinol Diabetes 2016; 124(08): 497-503
DOI: 10.1055/s-0042-103684
Article
© Georg Thieme Verlag KG Stuttgart · New York

Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot[*]

H. L. Qin
1   Department of Radiology, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, China
,
X. H. Zhu
1   Department of Radiology, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, China
,
B. Zhang
2   Department of Ultrasound in Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China
,
L. Zhou
1   Department of Radiology, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, China
,
W. Y. Wang
1   Department of Radiology, Affiliated Anhui Provincial Hospital, Anhui Medical University, Hefei, China
› Author Affiliations
Further Information

Publication History

received 29 August 2015
first decision 12 December 2015

accepted 23 February 2016

Publication Date:
24 May 2016 (online)

Preview

Abstract

Aims: The multilineage differentiation potential of human umbilical cord mesenchymal stem cells (HUCMSCs) holds therapeutic promise for non-healing ulcers and tissue regeneration. The present study evaluated the effects of HUCMSC transplantation after angioplasty for treatment of diabetic foot.

Methods: Included in the study were 53 patients (72 limbs) with severe symptoms of Fontaine II-IV diabetic foot accompanied by varying degrees of lower extremity arterial disease. The patients were randomly apportioned to a control group (25 patients; 38 limbs) or an experimental group (28 patients; 34 limbs). Patients of both groups received interventional treatment with angioplasty; those in the experimental group also received HUCMSCs by endovascular infusion and injection around the foot ulcer.

Results: Within the 3-month follow-up, relative to patients in the control group, those in the experimental group experienced significantly greater and more stable improvements in skin temperature, ankle-brachial pressure index, transcutaneous oxygen tension, and claudication distance. Notably, 3 months after treatment a significant increase in neovessels, accompanied by complete or gradual ulcer healing, was shown in the experimental group. In addition, no serious complications or adverse reactions were associated with the treatment.

Conclusion: Therefore, our results indicate that HUCMSC transplantation after angioplasty is a safe and effective clinical therapy for severe diabetic foot.

* Time and setting: This study was conducted at the Department of Interventional Radiology and Department of Endocrinology, First People’s Hospital of Hefei City and the Blood Center of Anhui Province from April 2011 to December 2013